Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SNDX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSyndax raises $250M through convertible notes at 35% premium to fund R&D and commercialization
Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Syndax issued $250M of 2.25% convertible senior notes due 2031 in a private placement, netting approximately $243M after fees. Funds will support working capital, R&D, commercialization activities, and business development.
Item 1.01 verify on EDGAR → -
high
Notes convert at $24.76 per share (35% premium to June 3 stock price), potentially issuing up to 13.6M shares. Initial conversion rate is 40.39 shares per $1,000 principal, subject to anti-dilution adjustments.
Item 1.01 & 3.02 verify on EDGAR → -
medium
Company cannot redeem notes before June 20, 2029. After that date, redemption allowed only if stock trades above 130% of conversion price for 20 of 30 consecutive trading days.
Item 1.01 verify on EDGAR → -
medium
Noteholders can force repurchase at 100% of principal plus accrued interest if a fundamental change occurs. Events of default include cross-default on debt exceeding $25M.
Item 1.01 verify on EDGAR → -
low
Notes sold in private placement under Section 4(a)(2) exemption. Future conversions to stock will use Section 3(a)(9) exemption, avoiding additional SEC registration requirements.
Item 3.02 verify on EDGAR →
Summary
Syndax Pharmaceuticals raised $250 million through a private placement of convertible senior notes, adding significant debt to its balance sheet while securing capital for operations and growth. The 2.25% notes mature in 2031 and convert into common stock at $24.76 per share—a 35% premium to the current stock price—potentially diluting shareholders by up to 13.6 million shares if fully converted.
The company will use the $243 million in net proceeds for general corporate purposes including R&D, commercialization of its pipeline, and business development activities. For retail investors, this financing provides Syndax with substantial runway to advance its drug development programs and commercial operations without immediate equity dilution.
However, the conversion feature creates potential future dilution if the stock performs well. The 35% conversion premium suggests management believes the stock has significant upside, as conversion becomes economically attractive only above $24.76 per share. Watch for updates on how Syndax deploys this capital, particularly any announcements about clinical trial progress, regulatory milestones, or commercial expansion that could justify the premium valuation implied by the conversion price. Also monitor the stock's performance relative to the $24.76 threshold, as crossing this level could trigger conversion activity and dilution.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) entered into privately negotiated subscription agreements (the “Subscription Agreements”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “Notes”).
The company raised $250 million through convertible senior notes with a 2.25% annual interest rate, maturing in 2031. The notes are convertible into common stock at an initial conversion price of approximately $24.76 per share, representing a 35% premium over the June 3, 2026 stock price. The notes can be converted under specific conditions before maturity and are redeemable by the company after June 20, 2029 if the stock price exceeds 130% of the conversion price.
Added in current filing · verify on EDGAR →
The Company estimates that the net proceeds from the Private Placement will be approximately $243 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for general corporate purposes, including working capital, research and development expenditures, commercialization activity expenditures and business development expenditures.
After fees and expenses, the company will receive approximately $243 million in net proceeds. These funds will be used for general corporate purposes including working capital, R&D spending, commercialization activities, and business development. This provides the company with significant capital flexibility for operations and growth initiatives.
Added in current filing · verify on EDGAR →
The conversion rate for the Notes will initially be 40.3894 shares of Common Stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $24.76 per share of Common Stock). The initial conversion price of the Notes represents a premium of approximately 35% over the last reported sale price of the Common Stock on the Nasdaq Global Select Market on June 3, 2026.
Each $1,000 of notes converts into 40.3894 shares of common stock, equivalent to a conversion price of $24.76 per share. This represents a 35% premium to the stock price on June 3, 2026. If converted, the notes could result in dilution of approximately 10.1 million shares (assuming full conversion of the $250 million principal amount).
Added in current filing · verify on EDGAR →
default by the Company or any of its significant subsidiaries (as defined in the Indenture) with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed with a principal amount in excess of $25,000,000 (or its foreign currency equivalent), in the aggregate of the Company and/or any such significant subsidiary
The indenture includes standard events of default such as failure to pay interest or principal, failure to convert notes when required, and cross-default provisions for other debt exceeding $25 million. If an event of default occurs, noteholders or the trustee can accelerate the notes, making the full principal and accrued interest immediately due and payable.
Event · Item 2.03 — Creation of a Direct Financial Obligation
Syndax Pharmaceuticals created a direct financial obligation, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The company disclosed the creation of a direct financial obligation under Item 2.03. The specific terms and details are referenced in Item 1.01 of this 8-K, which was not provided in the excerpt. This typically indicates new debt, credit facility, or similar financing arrangement.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Syndax sold convertible notes in a private placement; up to 13.6M shares may be issued upon conversion at initial rate of 54.5256 shares per $1,000.
Added in current filing · verify on EDGAR →
The Company offered and sold the Notes to certain investors in reliance on the exemption from registration provided by Section 4(a) (2) of the Securities Act of 1933, as amended (the “Securities Act”).
Syndax completed a private placement of convertible notes to certain investors without registering the securities under the Securities Act, relying on the Section 4(a)(2) exemption for private offerings. This is a capital-raising transaction that adds debt to the balance sheet while providing potential future equity dilution.
Added in current filing · verify on EDGAR →
Initially, a maximum of 13,631,400 shares of Common Stock may be issued upon conversion of the Notes based on the initial maximum conversion rate of 54.5256 shares of Common Stock per $1,000 principal amount of Notes, which is subject to customary anti-dilution adjustment provisions.
The notes are convertible into common stock at an initial rate of 54.5256 shares per $1,000 principal, which could result in up to 13,631,400 new shares being issued. This represents potential dilution to existing shareholders if the notes are converted, though the actual dilution depends on future conversion events and anti-dilution adjustments.
Added in current filing · verify on EDGAR →
To the extent that any shares of Common Stock are issued upon conversion of the Notes, they will be issued in transactions anticipated to be exempt from registration under the Securities Act by virtue of Section 3(a) (9) thereof as involving an exchange by the Company exclusively with its noteholders because no commission or other remuneration is expected to be paid in connection with conversion of the Notes and any resulting issuance of shares of Common Stock.
The company plans to rely on Section 3(a)(9) of the Securities Act when converting notes to shares, which exempts exchanges with existing security holders where no commission is paid. This means future conversions can occur without additional SEC registration, streamlining the conversion process.
Event · Item 8.01 — Other Events
Syndax priced convertible notes offering; proceeds use and terms disclosed in press release.
Added in current filing · verify on EDGAR →
On June 4, 2026, the Company issued a press release announcing the pricing of the Notes.
Syndax announced the pricing of convertible notes (referred to as 'the Notes') through a press release on June 4, 2026. The 8-K references the offering and anticipated use of net proceeds but does not provide specific terms such as interest rate, maturity date, conversion price, or total principal amount in the body text. These details would be in the attached press release (Exhibit 99.1).
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Press release entitled “Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes,” dated June 4, 2026
Syndax disclosed a private placement of $250 million in convertible senior notes. This represents a significant debt financing event that will add leverage to the balance sheet while providing capital for operations or growth initiatives. Convertible notes can dilute shareholders if converted to equity.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify